Excellent John K. Kumi is a cryptocurrency and fintech enthusiast, operations manager of a fintech platform, writer, researcher, and a huge fan of creative writing. With an Economics background, he finds much interest in the invisible factors that causes price change in anything measured with valuation. He has been in the crypto/blockchain space in the last five (5) years. He mostly watches football highlights and movies in his free time.
One of the regimens came out with 62% efficacy when administered for one month apart in two full doses. The other dosing regimen came out with an efficacy rate of 90% when administered for at least a month apart with a half dose followed by a full dose.
The COVID-19 vaccine being developed by AstraZeneca Plc (LON: AZN) in collaboration with the University of Oxford has appeared to have an efficacy of up to 90%. The last stage of the AstraZeneca vaccine trial was conducted in the UK and Brazil and is continuing in the US. According to the reports, it underwent two separate dosing regimens. One of the regimens came out with 62% efficacy when administered for one month apart in two full doses. The other dosing regimen came out with an efficacy rate of 90% when administered for at least a month apart with a half dose followed by a full dose. This means it has an average efficacy of 70%.
According to the Chief Investigator of the Oxford Vaccine Trial Professor Andrew Pollard, the results of the conducted trials indicates that they currently have a working vaccine that when applied can save many lives. Pollard explains that since one of their dosing regimens came out with an effective rate of 90%, more people could be vaccinated with that dosing regimen when an effective planned vaccine supply is carried out. He revealed that they will soon start the process of preparing a regulatory submission of data to authorities that have early approval or conditional approvals in such cases.
COVID-19 has claimed more than 1 million lives, and according to the CEO of AstraZeneca Pascal Soriot, this development is an important milestone in the fight against the global pandemic. The results of the AstraZeneca Vaccine trials comes as good news following the recent positive development announced by Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA).
It is worth noting that the AstraZeneca vaccine results did not come with a serious side effect or a safety event as both dosing regimens came out good. Soriot hinted that once the AstraZeneca Vaccine is approved, it would be made globally available and affordable to serve hundreds of millions of people. This is to satisfy their pledge of not prioritizing profits, but stay committed and ensure equitable and timely access.
Britain Accepts AstraZeneca COVID-19 Vaccine in Open Arms
Matt Hancock, the British Health Secretary received this news with a lot of excitement revealing that they have already made 100 million pre-orders, and once that goes well, they will go all out in the new year. Hancock also stated that regulators would need to consider whether the program that leads to the administration of the AstraZeneca COVID-19 vaccine to get the 90% efficacy is the appropriate way.
Having said that, Hancock stated that there is evidence in the report that establishes that the AstraZeneca Vaccine cannot only prevent people from contracting the virus but can also reduce the transmission. This follows the hint that people who got the regime with higher protection had a good chance of minimizing asymptomatic infections. He added that this is good news If confirmed to be true.
The UK has already ordered 40 million of the Pfizer and BioNtech vaccine that has shown the efficacy of 95%.